Triclabendazole

As one of the few therapeutic drugs specifically targeting fascioliasis worldwide, triclabendazole belongs to the benzimidazole class of anthelmintics. It exerts its anthelmintic effect by inhibiting the polymerization of helminth tubulin and blocking the energy metabolism pathway. It is a first-line therapeutic drug for fascioliasis in people of all age groups explicitly recommended by the WHO, and also has definite clinical efficacy against paragonimiasis, filling the gap of specific treatment in the field of chronic parasitic infections.

According to public data, the current global number of people infected with fascioliasis exceeds 17 million, with over 2 million new cases every year, driving the global market size of triclabendazole to maintain an annual growth rate of around 6%. The current market is dominated by generic drug supply, and regions with high incidence of parasitic diseases such as Africa and Southeast Asia are the core demand markets. In China, due to the remarkable achievements in parasitic disease prevention and control, market demand is concentrated in public health reserves and clinical use in special regions, and there is no relevant record of large-scale centralized procurement so far; if there is no verifiable data, it shall be indicated.

The original research enterprise of triclabendazole is Novartis Pharma AG of Switzerland, with the original brand name Egaten, and the core compound patent has expired globally. The main dosage form of the original drug is 250mg tablet, which has been included in the WHO Model List of Essential Medicines and is also listed in the FDA Reference Listed Drug Catalog. In China, at present, the triclabendazole APIs of a number of enterprises have obtained A status through CDE registration, and several oral preparation products have been approved for marketing. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO provides a full set of impurity reference standards for triclabendazole API. Most products are available directly from stock, and in-stock orders placed before 16:00 can be shipped on the same day. All products meet the requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA, and can provide stable and reliable reference standard support for pharmaceutical enterprises in the links of API R&D, quality control and registration declaration.